✦ LIBER ✦

New and different approaches needed for the design and execution of Alzheimer's clinical trials

✍ Scribed by Carrillo, Maria C.; Vellas, Bruno

Book ID: 122067057
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 182 KB
Volume: 9
Category: Article
ISSN: 1552-5260
DOI: 10.1016/j.jalz.2013.03.008

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Establishing the psychometric underpinni

Establishing the psychometric underpinning of cognition measures for clinical trials of Alzheimer's disease and its precursors: A new approach

✍ Posner, Holly B.; Cano, Stefan; Carrillo, Maria C.; Selnes, Ola; Stern, Yaakov; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 181 KB

The epidemiology of Alzheimer’s disease:

The epidemiology of Alzheimer’s disease: Laying the foundation for drug design, conduct, and analysis of clinical trials

✍ Kristine Yaffe; Michael Tocco; Ronald C. Petersen; Catherine Sigler; Leah C. Bur 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 193 KB

All-Cause Mortality Rate in Patients wit

All-Cause Mortality Rate in Patients with Idiopathic Pulmonary Fibrosis. Implications for the Design and Execution of Clinical Trials

✍ King, Talmadge E.; Albera, Carlo; Bradford, Williamson Z.; Costabel, Ulrich; du 📂 Article 📅 2014 🏛 American Thoracic Society 🌐 English ⚖ 693 KB

P4-343: Omega 3 fatty acids and Alzheime

P4-343: Omega 3 fatty acids and Alzheimer's disease: Trial design and baseline study population characteristics in a clinical trial of docosahexanoic acid for Alzheimer's disease

✍ Quinn, Joseph F.; Raman, Rema; Thomas, Ronald; Ernstrom, Karin; Yurko-Mauro, Kar 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 53 KB

The ADAS-cog and clinically meaningful c

The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease

✍ Kenneth Rockwood; Sherri Fay; Mary Gorman 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 2 views

## Abstract ## Background A minimum 4‐point change at 6 months on the Alzheimer's disease assessment scale‐cognitive subscale (ADAS‐cog) is deemed clinically important, but this cut‐point has been little studied in relation to clinical meaningfulness. In an investigator‐initiated, clinical trial o

Challenges to the Design, Execution, and

Challenges to the Design, Execution, and Analysis of Randomized Controlled Trials for Inflammatory Bowel Disease

✍ Geert D'Haens; Brian Feagan; Jean–Frédéric Colombel; William J. Sandborn; Walter 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 342 KB